Targeting enabled homolog with daunorubicin inhibits ERK1/2/c‐Fos pathway and suppresses hepatocellular carcinoma progression
| Published in: | Clinical and Translational Medicine |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Online Access: | https://doi.org/10.1002/ctm2.70366 |